Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168256 | 0.93 | CCR1 (0.41) | RENCCR1CHRM2CCR5SLC1A1 | |
| SCHEMBL6168988 | 0.91 | REN (0.35) | RENCCR1CHRM2CCR5SLC1A1 | |
| SCHEMBL6167965 | 0.90 | CSNK1E (0.38) | RENCCR1 | |
| SCHEMBL6167138 | 0.86 | F2RL1 (0.36) | RENCCR1CHRM2CCR5SLC1A1 | |
| SCHEMBL27585058 | 0.82 | — | — | |
| SCHEMBL6168253 | 0.80 | CSNK1E (0.37) | RENCCR1 | |
| SCHEMBL6167922 | 0.78 | CCR1 (0.42) | RENCCR1CHRM2CCR5SLC1A1 | |
| SCHEMBL6168085 | 0.78 | CCR1 (0.42) | RENCCR1CHRM2CCR5SLC1A1 | |
| SCHEMBL4062779 | 0.75 | CCR1 (0.51) | RENCCR1CHRM2CCR5SLC1A1 | |
| SCHEMBL6165747 | 0.75 | CCR1 (0.33) | CCR1CHRM2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | claimed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | claimed |
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132810-A1 | Novel heterocyclic amide derivatives | ARG1, IL4, ARG2 | REN 42/4885CCR1 32/4885CHRM2 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.